- Home
- TCPC vs PHAR Comparison
TCPC vs PHAR Comparison
Compare TCPC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCPC
- PHAR
- Stock Information
- Founded
- TCPC 2012
- PHAR 1988
- Country
- TCPC United States
- PHAR Netherlands
- Employees
- TCPC N/A
- PHAR N/A
- Industry
- TCPC Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- TCPC Finance
- PHAR Health Care
- Exchange
- TCPC Nasdaq
- PHAR Nasdaq
- Market Cap
- TCPC 767.3M
- PHAR 679.0M
- IPO Year
- TCPC 2012
- PHAR N/A
- Fundamental
- Price
- TCPC $8.96
- PHAR $9.55
- Analyst Decision
- TCPC Hold
- PHAR Strong Buy
- Analyst Count
- TCPC 7
- PHAR 3
- Target Price
- TCPC $8.88
- PHAR $27.00
- AVG Volume (30 Days)
- TCPC 557.7K
- PHAR 5.4K
- Earning Date
- TCPC 02-27-2025
- PHAR 03-13-2025
- Dividend Yield
- TCPC 15.14%
- PHAR N/A
- EPS Growth
- TCPC N/A
- PHAR N/A
- EPS
- TCPC N/A
- PHAR N/A
- Revenue
- TCPC $249,036,775.00
- PHAR $285,745,000.00
- Revenue This Year
- TCPC $27.36
- PHAR $20.08
- Revenue Next Year
- TCPC N/A
- PHAR $9.22
- P/E Ratio
- TCPC N/A
- PHAR N/A
- Revenue Growth
- TCPC 21.38
- PHAR 30.64
- 52 Week Low
- TCPC $7.71
- PHAR $6.65
- 52 Week High
- TCPC $11.77
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- TCPC 57.01
- PHAR 50.97
- Support Level
- TCPC $8.45
- PHAR $9.37
- Resistance Level
- TCPC $8.94
- PHAR $10.01
- Average True Range (ATR)
- TCPC 0.18
- PHAR 0.52
- MACD
- TCPC 0.04
- PHAR -0.10
- Stochastic Oscillator
- TCPC 87.93
- PHAR 28.08
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.